Evolus Inc
NASDAQ:EOLS

Watchlist Manager
Evolus Inc Logo
Evolus Inc
NASDAQ:EOLS
Watchlist
Price: 12.6 USD -3.37% Market Closed
Market Cap: 797.8m USD
Have any thoughts about
Evolus Inc?
Write Note

Relative Value

The Relative Value of one EOLS stock under the Base Case scenario is 21.5 USD. Compared to the current market price of 12.6 USD, Evolus Inc is Undervalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EOLS Relative Value
Base Case
21.5 USD
Undervaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
66
vs Industry
35
Median 3Y
3.6
Median 5Y
3.7
Industry
2.5
Forward
3
vs History
vs Industry
Median 3Y
-8.7
Median 5Y
-6.2
Industry
21.9
Forward
-44.9
vs History
vs Industry
Median 3Y
-11.5
Median 5Y
-9.4
Industry
16.5
vs History
vs Industry
1
Median 3Y
-11.7
Median 5Y
-9.8
Industry
23.6
vs History
3
vs Industry
1
Median 3Y
14
Median 5Y
6.1
Industry
2.1
vs History
58
vs Industry
32
Median 3Y
3.7
Median 5Y
3.8
Industry
2.6
Forward
3.1
vs History
71
vs Industry
40
Median 3Y
5.6
Median 5Y
5.7
Industry
5.2
vs History
vs Industry
Median 3Y
-11
Median 5Y
-9.4
Industry
13.3
Forward
429.9
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-8.2
Industry
16.6
Forward
974.7
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-8.2
Industry
15.6
vs History
vs Industry
Median 3Y
-10.1
Median 5Y
-7.9
Industry
19.1
vs History
14
vs Industry
14
Median 3Y
5.2
Median 5Y
4.3
Industry
1.9

Multiples Across Competitors

EOLS Competitors Multiples
Evolus Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Evolus Inc
NASDAQ:EOLS
797m USD 3.2 -14.4 -31.7 -26.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
US
Evolus Inc
NASDAQ:EOLS
Average P/E: 32.4
Negative Multiple: -14.4
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Evolus Inc
NASDAQ:EOLS
Average EV/EBITDA: 484.8
Negative Multiple: -31.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A
US
Eli Lilly and Co
NYSE:LLY
45.7
195%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
DK
Novo Nordisk A/S
CSE:NOVO B
24.3
84%
US
Johnson & Johnson
NYSE:JNJ
12.3
14%
US
Merck & Co Inc
NYSE:MRK
10.5
331%
CH
Roche Holding AG
SIX:ROG
9.9
23%
CH
Novartis AG
SIX:NOVN
10.1
8%
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
IE
E
Endo International PLC
LSE:0Y5F
234.4
N/A

See Also

Discover More
Back to Top